This content is strictly the opinion of Dr. Josh Axe and is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of medical advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. Neither Dr. Axe nor the publisher of this content takes responsibility for possible health consequences of any person or persons reading or following the information in this educational content. All viewers of this content, especially those taking prescription or over-the-counter medications, should consult their physicians before beginning any nutrition, supplement or lifestyle program.
Several weeks after a hysterectomy last spring, Bo Roth was suffering from exhaustion and pain that kept her on the couch much of the day. The 58-year-old Seattle speech coach didn’t want to take opioid pain-killers, but Tylenol wasn’t helping enough. Roth was intrigued when women in her online chat group enthused about a cannabis-derived oil called cannabidiol (CBD) that they said relieved pain without making them high. So Roth, who hadn’t smoked weed since college but lived in a state where cannabis was legal, walked into a dispensary and bought a CBD tincture.
Furthermore, this number is expected to grow. According to the CDC, it is estimated that by 2040, over 78 million adults will have arthritis that has been diagnosed by a doctor, with 43% of those individuals limited in terms of activity because of the disease, without taking into effect other conditions that contribute to arthritis side effects, like growing obesity numbers and more.
‘In doses used as a food supplement, CBD poses few risks, and side effects are unusual but can include a dry mouth or drowsiness,’ reveals Dr Brewer. ‘Higher doses used medically are well tolerated, and there are no serious safety concerns. A World Health Organization report issued in 2017 concluded that cannabidiol does not appear to have abuse potential or cause harm.'
Currently, the only CBD product approved by the Food and Drug Administration is a prescription oil called Epidiolex. It's approved to treat two types of epilepsy. Aside from Epidiolex, state laws on the use of CBD vary. While CBD is being studied as a treatment for a wide range of conditions, including Parkinson's disease, schizophrenia, diabetes, multiple sclerosis and anxiety, research supporting the drug's benefits is still limited.
The contents displayed within this public group(s), such as text, graphics, and other material ("Content") are intended for educational purposes only. The Content is not intended to substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your healthcare provider with any questions you may have regarding your medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in a public group(s).
Cannabidiol (CBD) has NOT been proven to treat, relieve, nor cure any disease or medical condition listed on this site. The medical studies, controlled tests, and health information offered on Cannabidiol Life of allcbdoilbenefits.com (or any variation of the URL) is an expressed summarization of our personal conducted research done by me and few friends in the business. The information provided on this site is designed to support, NEVER replace, the relationship that exists between a patient/site visitor and the patient’s/site visitor’s physician.
Current protocols include managing ADHD with a combination of behavioral therapy and medications. Numerous medications, both stimulants and non-stimulants, have been approved by the Food and Drug Administration (FDA) to treat ADHD. Because each individual reacts differently to each medication, finding an appropriate protocol can be a challenge associated with many negative symptoms, including:
More recent experiments, involving the administration of a part CBD part THC solution, have yielded results that contradict the first supposition. At present, on the evidence that cannabidiol reduces some of the psychoactive effects of tetrahydrocannabinol (acting as a de facto antidepressant), scientists argue that cannabidiol has a holistic but indirect influence on all cannabinoid receptors in the endocannabinoid system. The main consequence of this impact seems to be an increase in the production of endocannabinoids. This is now the prevailing idea that accounts for the mountains of empirical evidence of how the benefits of cannabidiol are expressed at the cellular level.